Primary resistance to IDH inhibitors is primarily associated with leukemia stemness, while acquired resistance is often conferred by mutations in the genes belonging to the RUNX1/CEBPA or RAS-receptor tyrosine kinase (TK) pathways or genes such as BCOR, and TET2[63]. Here, IDH1 is linked to leukemia.